Search

Author/Creator Scartozzi, M.

3. 118P Immunosenescence and response to immunotherapy in elderly patients: A possible prognostic tool. (December 2022)

Authors:
Pretta, A.; Donisi, C.; Ziranu, P.; Liscia, N.; Loi, F.; Saba, G.; Pretta, G.; Spanu, D.; Dubois, M.; Atzori, F.; Pusceddu, V.; Puzzoni, M.; Massa, E.; Madeddu, C.; Lai, E.; Astara, G.; Scartozzi, M.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 2390 LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy. (September 2015)

Authors:
Faloppi, L.; Del Prete, M.; Casadei Gardini, A.; Santini, D.; Silvestris, N.; Bianconi, M.; Giampieri, R.; Bittoni, A.; Andrikou, K.; Valgiusti, M.; Brunetti, O.; Scartozzi, M.; Cascinu, S.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S467
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 65P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population. (December 2022)

Authors:
Rimini, M.; Casadei Gardini, A.; Persano, M.; Suda, G.; Tada, T.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Rimassa, L.; Presa, J.; Masi, G.; Yoo, C.; Lonardi, S.; Tovoli, F.; Piscaglia, F.; Iavarone, M.A.; Scartozzi, M.; Burgio, V.; Cascinu, S.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. 67P Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. (December 2022)

Authors:
Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Rimassa, L.; Presa, J.; Masi, G.; Yoo, C.; Lonardi, S.; Piscaglia, F.; Burgio, V.; Scartozzi, M.; Cascinu, S.; Casadei Gardini, A.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma. (February 2019)

Authors:
Iavarone, M.; Galmozzi, E.; De Silvestri, A.; Casadei-Gardini, A.; Piscaglia, F.; Marisi, G.; Facchetti, F.; Faloppi, L.; Ielasi, L.; Tovoli, F.; Cimino, A.; Scartozzi, M.; Cascinu, S.; Sangiovanni, A.; Tinelli, C.; Lampertico, P.
Journal:
Digestive and liver disease
Issue:
Volume 51(2019)Supplement 1
Page Start:
e38
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗